RU2159116C1 - Method for applying activation therapy to treat diseases - Google Patents

Abstract

FIELD: medicine. SUBSTANCE: method involves per os administering ASD fraction 2 preparation at an effective day dose of 20-250 drops dissolved in 70-200 ml of water. The dose and scheme of its consumption (daily, every second day, every third day, 15-45 min before taking meals, 40 min later after taking meals) depend on disease, organism response type, concomitant gastroenteric tract disease. The preparation can be taken with 3-5 days long pauses. EFFECT: wide range of applications as all-purpose adaptogenic preparation. 7 cl

Description

 The present invention relates to medicine, in particular to therapy, oncology, allergology, and can be used in the treatment of a wide range of diseases, as well as their prevention.

 All diseases are realized in a macroorganism, and the level of health, resistance to diseases and loads, the severity of the disease, and even the effectiveness of a specific treatment depend on the state of activity of its regulatory and protective subsystems. Therefore, today a special place is given to activation therapy - therapy by calling and maintaining antistress reactions in the body - mainly activation reactions of high levels of reactivity. By causing the development of an activation reaction, we thereby increase the functional activity of the regulatory and protective subsystems of the body to upper limits of the norm, improve synchronization within the body and the body with environmental factors, increase resistance, normalize homeostasis / Garkavi L.Kh. et al. Antistress reactions and activation therapy, 1998 /.

 Activation therapy is indicated for almost everyone, one for healing, another for prevention, and a third for treatment, either alone or in combination with a wide variety of therapies and surgical procedures. The principle of activation therapy - the targeted challenge of antistress reactions that determine the functional state of the body, characteristic of health - eliminates contraindications for the state of the body.

 Currently, activation therapy uses biostimulants of animal and plant origin.

 Immunomodulators of animal origin are known - a series of drugs of arbitrary natural interferon from human leukocytes: interferon alpha, interferon alpha 2a, interferon alpha 2c, etc. / Vidal Handbook, 1995, p. 485-486 /. The immunomodulatory activity of these drugs is associated with the activation of phagocytosis, stimulation of the formation of antibodies and lymphokines, and stimulation of the activity of NK cells. However, having a protein nature and being full-fledged antigens, these drugs have bright side effects: flu-like symptoms - fever, headache, myalgia, weakness; loss of appetite, nausea, vomiting, diarrhea, granulocytopenia, thrombocytopenia, hypotension, proteinuria, arrhythmia, impaired consciousness, ataxia, alopecia, skin rash, impaired liver function. Such manifestations limit the possibility of using preparations of interferon derivatives.

 Known drug Glutoxim / approved for medical use by Order of the Ministry of Health of the Russian Federation for N 279 from 09/22/1998 /. It relates to adaptogens of immunoregulatory and hematopoietic nature. It has the ability to prevent the inhibition of hematopoiesis, enhances immune defense in various infections and tumor processes, and inhibits the spread of tumors. Glutoxim is administered systemically / intravenously, intramuscularly, subcutaneously / or regionally / intraperitoneally, intrahepatic, intrapleural /.

 However, it was noted that in a number of patients the temperature may increase and pain may appear at the injection site, cases of individual intolerance to the drug were noted, the drug is contraindicated during lactation and pregnancy.

 The need for parenteral administration of Glutoxim for long courses of therapy with the presence of the above adverse reactions and contraindications limits the use of this drug.

 The task of the invention is the development of an effective method of activation therapy that does not have side effects, easy to use.

 The known drug ASD fractions 2 and 3. Approved in 1951 by the Pharmacological Committee of the Scientific Medical Council of the USSR Ministry of Health. Adopted for the treatment of a number of human skin diseases / eczema, neurodermatitis, sycosis, epidermophytosis, etc. /, as well as an anti-inflammatory drug / N. P. Toropova, O.A.Sinyavskaya. Eczema and atopic dermatitis in children. Yekaterinburg, 1993, pp. 336-339 /.

 However, this is far from a complete spectrum of effects on the body of the drug ASD.

 It is known that the drug ASD acts on the nerve cholinergic structures and increases the functional activity of the cholinergic system of acetylcholine-acetylcholinesterase as a whole / Z. I. Deryabin Agricultural. Biology N 6, M., 1980, p. 887-891 /.

 It has an adrenergic effect, manifests itself as catecholamines and activates the adenylate cyclase enzyme. Prevents the inhibitory effect of hydrocortisone on the lymphoid organs and adrenal glands / B.A. Timofeev et al. Reports VASKHNIL February 2, 1987, M., p. 32-34 /.

 It is also known that, against the background of the use of the drug ASD, activation of nonspecific and specific parts of the immune defense is noted. The concentration of properdine in the blood serum increases, the compliment system is activated, phagocytosis, the amount is normalized. B-lymphocytes, the level of immunoglobulins tends to normal, relationships are restored in the subpopulations of T-lymphocytes / Z. I. Deryabin, A.V. Nikolayev. Proceedings of the VIEV, Volume 35, M., 1968, p. 336 /.

 In this case, under the influence of the drug ASD, the reserve alkalinity of the blood / A increases. V. Dorogov, A.P. Voloskova. Proceedings of the VIEV, Volume 35, M., 1968, p. 332 /.

 The body creates optimal conditions for the neutralization of unoxidized radicals. The value of pulmonary gas exchange increases, the arteriovenous difference in oxygen and oxygen capacity of the blood increases, and tissue oxygen consumption increases. All this activates energy metabolism and oxidative processes in tissues / A.V. Dorogov, Z.I. Deryabin. Proceedings of the VIEV, Volume 35, M., 1968, p. 332-333 /.

 ASD has a stimulating effect on biochemical processes associated with the biological function of active sulfhydryl groups and is able to intensify many aspects of the metabolism of carbohydrates, lipids, proteins. The high content of choline derivatives determines its participation in lipid metabolism, in methylation processes, in the formation of the structure and functional activity of cell membranes. Under the influence of ASD revealed a significant increase in the content of nucleic acids (RNA) in the blood.

 This indicates an increase in the biosynthesis of protein substances in the body. The drug Dorogova activates trophic processes in tissues, increases metabolism in a healthy body and restores metabolic processes if they are disturbed in various diseases / Z.I.Deryabin Selskhozkhoz. Biology N 6. M., 1980, p. 887-891 /.

 The bactericidal effect of the drug is manifested in high concentrations and with prolonged exposure. Under the influence of the drug, some microbes lose virulence. General antiseptic activity includes, in addition to its direct effect on the microflora, the effect of increasing blood bactericidal activity, activation of non-specific factors of immune defense / V.A. Plotnikova et al. Proceedings of VGNKI. Volume 28.M., 1978, p. 130-135 /.

 The above studies suggest that the drug ASD affects almost all the links of the defense of a living organism, as a universal adaptogen. This is the technical result of the impact.

 In 1998, a patent of the Russian Federation for N 2099068 for the use of ASD as an antitumor agent was granted. This work was performed at the Arkhangelsk Medical Academy, based on experimental material. There are no data on clinical use and effective doses.

 The applicant has information that the drug ASD was successfully used by the author in clinical trials for the treatment of skin diseases / eczema, epidermophytosis, atopic dermatitis, psoriasis, sycosis, lichen /; hypertension, bronchial asthma, gastrointestinal diseases, purulent septic diseases, neuritis, neuralgia, in dental practice, with tuberculosis and malignant tumor lesions of the stomach, lungs, genitals. The results of these tests are not published in open press.

 Continuing the study of the therapeutic effect of the drug ASD in various diseases, we came to the conclusion that its main normalizing effect is mediated through high defense systems - the central nervous system, autonomic nervous system and neurohumoral regulation. By sequentially activating the endocrine and immune systems of the body, ASD prevents or reduces the inhibitory effect of glucocorticoids, inhibits the suppression of the thymic-lymphatic system, and thereby prevents the development of immunopathy under stress.

 In tissues, the effect of the drug is realized through the activation of a number of enzyme systems. One of the main biological components of the preparation of ASD f-2 are choline esters of carboxylic acids such as acetylcholine, butylcholine, propionylcholine, which have a pronounced acetylcholine-like effect. Acetylcholine is one of the main regulators of life processes in the body, performs not only mediator, but also trophic function, participates in the intracellular regulation of metabolism by affecting the permeability of cell membranes and the activity of various enzymes, enhances the synthesis of adrenaline, RNA, protein, increases oxygen uptake by tissues , promotes the activation of transport of RNA, amino acids, sugars, electrolytes through the membranes of red blood cells, skeletal muscles, blood vessels. Under the influence of the ASD drug, the level of free acetylcholine in the blood of rabbits rises by 9.6%, the activity of acetylcholinesterase increases by 34%, which indicates the activation of the function of the acetylcholine acetylcholinesterase system and, therefore, the stimulating effect of the drug on trophic processes in the body.

 The drug ASD has a selective effect on the functional structures of cell membranes, activating or inhibiting / depending on the concentration / enzyme N, K-ATPase. Thus, in moderate concentrations, the drug enhances the active transport of ions and metabolic substances through cell membranes, and in high concentrations inhibits the function of the metabolic pump. The preparation of ASD contains functionally active sulfhydryl groups characterized by high reactivity. Sulfhydryl groups take part in a number of physiological and biochemical processes: in nervous activity, in muscle contraction, cell division, regulation of mitochondrial membrane permeability, phosphorylation, etc. /A. Leninger, 1976; Yu.M. Torchinsky, 1971 /.

 We can talk about the regulation in the body of the processes of metabolism of carbohydrates, proteins and lipids under the influence of the drug ASD. It increases the activity of the RNase enzyme, increases the content of nucleic acids, total protein and gammaglobulins in the blood.

 All these mechanisms to a large extent explain the prophylactic and therapeutic effect of the drug ASD in a wide range of diseases. When choosing therapeutic tactics, it is necessary to take into account the type of disease, the phase of the pathological process, as well as the specifics of the response of this organism.

 For many years, we have developed and tested the method of using the drug ASD fraction 2 for a variety of diseases. The basic principles of choosing the dose and duration of the course of treatment, which are individual in each particular case and depend mainly on the weight of the patient, the type of disease and the type of response of the body, are identified.

 For the convenience of evaluating the type of response, we use the homeopathic concept of chronic miasma. If the patient is in sycosis (hyperfunction, hypertrophy), the therapeutic dose is reached within 6-10 days. If the patient is in a state of syphilitic miasma (perverse reactions with destruction elements), the required dose is reached more slowly - up to two weeks (12-14 days). If psora predominates in the patient’s condition (hypofunction, hypotrophy), the required daily dose is also reached within 12-14 days, but the dose does not increase spasmodically, as in the previous case, but more gradually over the entire period. The drug is diluted in 70-100 ml of water (each single dose) and taken orally. The daily dose of the drug varies from 1-40 drops at the beginning of treatment to 250-300 drops. During the treatment period, the dose of ASD may vary depending on the change in the patient’s condition and the prevalence of reactions of the currently leading miasma. When choosing a dose, it is necessary to take into account not only the nature of the underlying disease, but also the presence of a concomitant pathology of the gastrointestinal tract - take 15, 45 minutes before meals or 40 minutes after meals. Typically, patients take a daily dose in 2-4 doses, daily, every other day or two days, interruptions in admission up to 3-5 days are possible.

 The methods of taking the drug developed by the applicant for each particular nosological form are not the subject of the present invention, but are generally based on the above principles.

 The proposed method of activation therapy and its results are demonstrated by the following specific examples of use.

 Patient I., born in 1990, the city of Petropavlovsk-Kamchatsky. Born eight months old, screamed right away. At the age of one month after BCG vaccination, enteropathy, toxicoderma developed. Vaccination was no longer carried out. Grew and developed normally. 1992 - inpatient treatment for enterocolitis, then inpatient treatment for acute bronchitis, bronchial obstruction was first recorded. The end of 1992 inpatient treatment of right-sided segmental pneumonia. Adenoids II Art. Adenotomy 1993 year. Then again inpatient treatment of acute bronchitis. First diagnosed with obstructive bronchitis. He received treatment with myolitics, the course of Zaditen. In 1994, the diagnosis was made: bronchial asthma 1 atonic form of moderate severity. Allergic rhinosinusopathy. Examination by an allergist (1996) revealed an allergy to house dust, library dust and feather pillows. By the start of treatment with ASD (January 1999), asthmatic attacks are usually 1 time per month, and from December to May - 2 and in July once a month. The treatment was carried out with Zaditen, Ketotifen - without effect. He constantly takes Teotard, Tiled, Ventolin or Salbutomol, Eufillin and other drugs. At the time of inspection of normosthenic physique, normal nutrition. The skin is pale, clean. Palpation of the submandibular and cervical lymph nodes up to 0.5 cm in size. Pink mucous pharynx, tonsil hypertrophy. Auscultation is hard breathing, no wheezing. During the attack, breathing is hard, scattered dry rales on the front and back of the chest. During an attack, it can only be in a sitting or standing position. Heart sounds are loud, rhythmic, slight systolic murmur at the apex. The abdomen is soft, painless. Liver and spleen along the edge of the costal arch. During exacerbation of bronchial asthma or after an excitement - bedwetting. In January 1999, treatment with the drug ASD fraction 2 was started according to an individually selected scheme: patient weight 30 kg, age 9 years. Given the weight of the patient, his daily dose should be 0.1 ml • 30 kg = 3 ml, but the patient’s age is 9 years old, so we gave 1/3 of the adult dose - 13-14 drops. The dose was divided into 2 doses and each single dose (7 drops) was diluted in 70 ml of water, taken 15 minutes before meals. The required daily dose was reached as follows: 3 days - 3 drops x 2 times a day; 3 days - 5 drops x 2 times a day; then - 7 drops x 2 times a day.

 By the end of January, asthma attacks stopped, and an abundant and easy discharge of sputum began and proceeded for about a month. There were rashes on the palms. In April there was an episode of acute respiratory viral infection, which was not complicated by bronchospastic syndrome for the first time, rashes on the palms disappeared. Re-inspection in May 1999. Satisfactory condition, no complaints. There are no attacks of suffocation and active asphyxiating cough. Lymph nodes are not enlarged, vesicular breathing in the lungs, no wheezing. Dose adjustment was carried out: take 3 drops x 1 time per day, 5 - days to drink, 2 - days off. During the year there was not a single attack of suffocation.

 Patient K., born in 1950.

 Since 1991, episodes of arterial hypertension have been reported. Since 1982, he suffers from peptic ulcer of the duodenum, annually underwent examination and treatment in a hospital. In March 1994, when examining a hypertensive disease at the Central Military Research Aviation Hospital, a tumor of the right kidney was detected, and a resection of the right kidney was performed on 05.16.94. Diagnosis: TINOMO right kidney cancer. Histological examination: clear cell carcinoma of the kidney. In connection with the deterioration, it is directed to the CWC. In April 1996, lower back pain appeared with radiation to the right leg. From 02.10. to 10.26.96 years examined in TsVKG them. Burdenko. Diagnosed with cancer of the right kidney. Condition after resection of the right kidney. L4 spine metastases with compression of the dural sac of the right L5 root of the spinal cord. A course of radiation therapy was carried out with the goal of anesthesia in the area L3-L5 SOD = 40 Gy. Recommended discharge corset for continuous wear. In November-December 1996, the condition progressively worsened. At the time of starting treatment with ASD in January 1997, the patient did not go out on the street, basically lay, struggled to move around the apartment, constantly took narcotic painkillers - Promedol. The treatment was started taking into account the fact that the patient was dominated by sycotic type reactions, and the weight was 80 kg. Dose calculation: 0.1 ml • 80 kg = 8 ml, which corresponds to 100-120 drops; the dose was divided into 4 doses, each single dose corresponded to 30 drops of ASD diluted in 100 ml of water. Given the patient’s history of duodenal ulcer, each single dose was taken 40 minutes after eating. Exit to the required daily dose was carried out gradually: 3 days 10 cap. x 4 times a day; 3 days 15 cap. x 4 times a day; 3 days 20 cap. x 4 times a day; then 30 drops x 4 times a day. During treatment, the patient's condition gradually improved. By April 1997, the patient began to actively move with the help of a wand. The dose of painkillers decreased to 1 injection of Promedol per day, however, the wife noted signs of a formed drug dependence. In August 1997, he was hospitalized in the neuropsychiatric department, where the patient completely refused narcotic drugs. Computer study of the spine from 2.11.98, TsNAG.

 Computed tomography of the lumbar spine at the level of L3-L4-L5 vertebral segments compared with the study data from August 8, 1997 determines the pronounced regional sclerosis of the foci of destruction of the body of the L4 vertebra. There were no signs of progression of the underlying disease. CT scan of the abdominal cavity: the right kidney in the upper sections is deformed, probably due to the postoperative adhesive process. The phenomena of chronic cholecystopancreatitis. In November 98, the patient felt well, moved easily, without a wand, pain was practically not disturbed. At the end of 1998, he independently abandoned maintenance therapy with ASD.

 The applicant has observations, where the use of ASD fraction 2 led to significant clinical improvement in patients: tuberculosis of the kidney, lungs, spine; hypertension and coronary heart disease; acute and chronic non-specific lung diseases; chronic gastritis, colitis, peptic ulcer of the stomach and duodenum; acute and chronic pyelonephritis, cystitis; acute and aphonic forms of adnexitis, salpingo-oopitis, endometritis, prostatitis; skin diseases (neurodermatitis, psoriasis, eczema, alopecia, microbial and fungal infections of the skin). In the treatment of skin lesions externally used balms based on ASD fraction N 3.

Claims (7)

 1. The method of activation therapy of diseases, including the ingestion of a drug, characterized in that the drug is used as an ASD, fraction 2 in an effective daily dose, depending on the type of disease and the type of response of the body.  2. The method according to claim 1, characterized in that the effective daily dose of ASD is 20 to 250 drops.  3. The method according to claim 1 or 2, characterized in that the ASD is taken by dissolving a single dose in 70-200 ml of water.  4. The method according to claim 1, or 2, or 3, characterized in that the output at an effective daily dose is carried out for 1 to 14 days, depending on the type of response of the body, starting from 1 to 40 drops per day.  5. The method according to claim 1, or 2, or 3, or 4, characterized in that the intake regimen is selected individually, every other day, after 2 days.  6. The method according to claim 1, characterized in that the ASD is taken orally 15, 45 minutes before eating or 40 minutes after eating, depending on concomitant diseases of the digestive system.  7. The method according to claim 1, characterized in that interruptions in taking the drug from 3 to 5 days are possible.